JP2014517279A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014517279A5 JP2014517279A5 JP2014510475A JP2014510475A JP2014517279A5 JP 2014517279 A5 JP2014517279 A5 JP 2014517279A5 JP 2014510475 A JP2014510475 A JP 2014510475A JP 2014510475 A JP2014510475 A JP 2014510475A JP 2014517279 A5 JP2014517279 A5 JP 2014517279A5
- Authority
- JP
- Japan
- Prior art keywords
- mucosal healing
- individual
- markers
- combinations
- index
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000035876 healing Effects 0.000 claims 31
- 238000000034 method Methods 0.000 claims 20
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 14
- 238000011269 treatment regimen Methods 0.000 claims 8
- 230000001225 therapeutic effect Effects 0.000 claims 7
- 238000011282 treatment Methods 0.000 claims 7
- 239000003550 marker Substances 0.000 claims 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims 4
- 208000011231 Crohn disease Diseases 0.000 claims 4
- 108010008165 Etanercept Proteins 0.000 claims 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 238000012896 Statistical algorithm Methods 0.000 claims 3
- 229960002964 adalimumab Drugs 0.000 claims 3
- 229960000403 etanercept Drugs 0.000 claims 3
- 229940048921 humira Drugs 0.000 claims 3
- 229960000598 infliximab Drugs 0.000 claims 3
- 229940116176 remicade Drugs 0.000 claims 3
- 102100038778 Amphiregulin Human genes 0.000 claims 2
- 101800001382 Betacellulin Proteins 0.000 claims 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 2
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 2
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 claims 2
- 102100037665 Fibroblast growth factor 9 Human genes 0.000 claims 2
- 102000018710 Heparin-binding EGF-like Growth Factor Human genes 0.000 claims 2
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 claims 2
- 102100021866 Hepatocyte growth factor Human genes 0.000 claims 2
- 101000809450 Homo sapiens Amphiregulin Proteins 0.000 claims 2
- 101001060261 Homo sapiens Fibroblast growth factor 7 Proteins 0.000 claims 2
- 101001027380 Homo sapiens Fibroblast growth factor 9 Proteins 0.000 claims 2
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 claims 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 2
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims 2
- 101001109792 Homo sapiens Pro-neuregulin-2, membrane-bound isoform Proteins 0.000 claims 2
- 101001109765 Homo sapiens Pro-neuregulin-3, membrane-bound isoform Proteins 0.000 claims 2
- 101001109767 Homo sapiens Pro-neuregulin-4, membrane-bound isoform Proteins 0.000 claims 2
- 101001056707 Homo sapiens Proepiregulin Proteins 0.000 claims 2
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 claims 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims 2
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 claims 2
- 102000048238 Neuregulin-1 Human genes 0.000 claims 2
- 108090000556 Neuregulin-1 Proteins 0.000 claims 2
- 101710098940 Pro-epidermal growth factor Proteins 0.000 claims 2
- 102100022668 Pro-neuregulin-2, membrane-bound isoform Human genes 0.000 claims 2
- 102100022659 Pro-neuregulin-3, membrane-bound isoform Human genes 0.000 claims 2
- 102100022658 Pro-neuregulin-4, membrane-bound isoform Human genes 0.000 claims 2
- 102100029837 Probetacellulin Human genes 0.000 claims 2
- 102100025498 Proepiregulin Human genes 0.000 claims 2
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 claims 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims 2
- 102100024584 Tumor necrosis factor ligand superfamily member 12 Human genes 0.000 claims 2
- 101710097155 Tumor necrosis factor ligand superfamily member 12 Proteins 0.000 claims 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 2
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 claims 2
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 claims 2
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 claims 2
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims 2
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 claims 2
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 claims 2
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 claims 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- 230000007246 mechanism Effects 0.000 claims 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims 2
- 238000011903 nutritional therapy Methods 0.000 claims 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 238000011285 therapeutic regimen Methods 0.000 claims 2
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 2
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- -1 IL-1β Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 claims 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 102000004890 Interleukin-8 Human genes 0.000 claims 1
- 229940121730 Janus kinase 2 inhibitor Drugs 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 1
- 229960002170 azathioprine Drugs 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 229960003115 certolizumab pegol Drugs 0.000 claims 1
- 229940090100 cimzia Drugs 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 230000037213 diet Effects 0.000 claims 1
- 235000005911 diet Nutrition 0.000 claims 1
- 229940073621 enbrel Drugs 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229960001428 mercaptopurine Drugs 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161484607P | 2011-05-10 | 2011-05-10 | |
| US61/484,607 | 2011-05-10 | ||
| US201161505026P | 2011-07-06 | 2011-07-06 | |
| US61/505,026 | 2011-07-06 | ||
| US201161553909P | 2011-10-31 | 2011-10-31 | |
| US61/553,909 | 2011-10-31 | ||
| US201161566509P | 2011-12-02 | 2011-12-02 | |
| US61/566,509 | 2011-12-02 | ||
| US201261636575P | 2012-04-20 | 2012-04-20 | |
| US61/636,575 | 2012-04-20 | ||
| PCT/US2012/037375 WO2012154987A1 (en) | 2011-05-10 | 2012-05-10 | Methods of disease activity profiling for personalized therapy management |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017225123A Division JP2018072349A (ja) | 2011-05-10 | 2017-11-22 | 個別治療管理のための疾患活動性プロファイリングの方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014517279A JP2014517279A (ja) | 2014-07-17 |
| JP2014517279A5 true JP2014517279A5 (cg-RX-API-DMAC10.html) | 2015-06-25 |
Family
ID=46147068
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014510475A Pending JP2014517279A (ja) | 2011-05-10 | 2012-05-10 | 個別治療管理のための疾患活動性プロファイリングの方法 |
| JP2017225123A Ceased JP2018072349A (ja) | 2011-05-10 | 2017-11-22 | 個別治療管理のための疾患活動性プロファイリングの方法 |
| JP2020006298A Pending JP2020098213A (ja) | 2011-05-10 | 2020-01-17 | 個別治療管理のための疾患活動性プロファイリングの方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017225123A Ceased JP2018072349A (ja) | 2011-05-10 | 2017-11-22 | 個別治療管理のための疾患活動性プロファイリングの方法 |
| JP2020006298A Pending JP2020098213A (ja) | 2011-05-10 | 2020-01-17 | 個別治療管理のための疾患活動性プロファイリングの方法 |
Country Status (14)
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110229471A1 (en) | 2008-11-26 | 2011-09-22 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease |
| CA3295783A1 (en) | 2011-05-10 | 2026-03-02 | Prometheus Laboratories, Inc. | Methods of disease activity profiling for personalized therapy management |
| WO2014113804A1 (en) * | 2013-01-21 | 2014-07-24 | Abbvie Inc. | Anti-tnf and anti-il17 combination therapy biomarkers for inflammatory disease |
| CN105228641A (zh) * | 2013-03-21 | 2016-01-06 | 密歇根大学董事会 | 治疗代谢紊乱的方法 |
| EP3022295A4 (en) | 2013-07-19 | 2017-03-01 | Cedars-Sinai Medical Center | Signature of tl1a (tnfsf15) signaling pathway |
| WO2015110989A1 (en) * | 2014-01-23 | 2015-07-30 | Nestec S.A. | Biomarker panel for assessment of mucosal healing |
| EP3129507A4 (en) * | 2014-04-10 | 2017-12-06 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Methods and kits for determining a personalized treatment regimen for a subject suffering from a pathologic disorder |
| WO2015166461A1 (en) | 2014-05-01 | 2015-11-05 | Nestec S.A. | Methods of selecting treatment regimen using tnf alpha and anti-tnf alpha drug levels |
| RU2016147569A (ru) * | 2014-05-09 | 2018-06-13 | Ногра Фарма Лимитед | Способы лечения воспалительного заболевания кишечника |
| US20170105647A1 (en) * | 2014-05-15 | 2017-04-20 | Children's Medical Center Corporation | Systems and methods for identifying neurobiological biomarkers using eeg |
| MX2017004742A (es) | 2014-10-20 | 2017-07-20 | Nestec Sa | Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos. |
| JP2018504584A (ja) * | 2014-12-02 | 2018-02-15 | ネステク ソシエテ アノニム | 過敏性腸疾患患者を治療するためのベドリズマブの投与計画を確立する方法 |
| RU2017122720A (ru) | 2014-12-05 | 2019-01-10 | Нестек С.А. | Непрямые однородные анализы по изменению подвижности для детекции биологических препаратов в образцах пациента |
| JPWO2016199180A1 (ja) * | 2015-06-09 | 2018-04-12 | 国立大学法人大阪大学 | 生物学的製剤による関節リウマチの治療効果の予測判定方法 |
| ES3067417T3 (en) | 2015-08-11 | 2026-05-21 | Cognoa Inc | Apparatus to determine developmental progress with artificial intelligence and user input |
| US11972336B2 (en) | 2015-12-18 | 2024-04-30 | Cognoa, Inc. | Machine learning platform and system for data analysis |
| CN109462996A (zh) | 2016-03-17 | 2019-03-12 | 西达-赛奈医疗中心 | 通过rnaset2诊断炎性肠病的方法 |
| CN109414461A (zh) * | 2016-04-26 | 2019-03-01 | 曲生物制品公司 | 治疗性地触发靶组织中的先天性免疫应答 |
| KR20230003433A (ko) | 2016-05-20 | 2023-01-05 | 세다르스-신나이 메디칼 센터 | 유전자에 기반한 염증성 장 질환의 진단 |
| GB201611738D0 (en) * | 2016-07-05 | 2016-08-17 | Cambridge Entpr Ltd | Biomarkers for inflammatory bowel disease |
| WO2018081175A1 (en) | 2016-10-24 | 2018-05-03 | Habit, Llc | System and method for implementing meal selection based on vitals, genotype, and phenotype |
| CN118609834A (zh) | 2016-11-14 | 2024-09-06 | 科格诺亚公司 | 用于评估发育状况并提供覆盖度和可靠性控制的方法和装置 |
| WO2018085937A1 (en) * | 2016-11-14 | 2018-05-17 | Qu Biologics Inc. | Managing site specific ibd immunotherapies |
| JP7324709B2 (ja) * | 2017-02-09 | 2023-08-10 | コグノア，インク． | デジタル個別化医療のためのプラットフォームとシステム |
| US20220254461A1 (en) * | 2017-02-09 | 2022-08-11 | Cognoa, Inc. | Machine learning algorithms for data analysis and classification |
| KR20200009095A (ko) | 2017-05-31 | 2020-01-29 | 프로메테우스 바이오사이언시즈, 인크. | 크론병 환자에서 점막 치유를 평가하는 방법 |
| JP7328960B2 (ja) | 2017-10-10 | 2023-08-17 | プロメテウス バイオサイエンシーズ インコーポレイテッド | ベドリズマブ処置をモニタリングするための方法 |
| US11270800B1 (en) * | 2017-11-09 | 2022-03-08 | Aptima, Inc. | Specialized health care system for selecting treatment paths |
| KR102424222B1 (ko) * | 2017-11-13 | 2022-07-21 | 더 멀티플 마이얼로머 리서치 파운데이션, 인크. | 통합된, 분자, 체학, 면역요법, 대사, 후성적, 및 임상 데이터베이스 |
| WO2019178546A1 (en) | 2018-03-16 | 2019-09-19 | Scipher Medicine Corporation | Methods and systems for predicting response to anti-tnf therapies |
| JP2020028278A (ja) * | 2018-08-24 | 2020-02-27 | 国立大学法人九州大学 | 被検体に生じるイベントを予測するための判別器の生成方法、及び前記判別器を用いた被検体の層別化方法 |
| WO2020112890A1 (en) | 2018-11-29 | 2020-06-04 | Cedars-Sinai Medical Center | Rnaset2 compositions and methods of treatment therewith |
| CA3121167A1 (en) * | 2018-11-29 | 2020-06-04 | Cedars-Sinai Medical Center | Methods of stratifying and treating a sub-population of inflammatory bowel disease patients |
| CN113873935B (zh) | 2019-03-22 | 2024-11-22 | 科格诺亚公司 | 个性化数字化治疗方法和装置 |
| CN109998488B (zh) * | 2019-04-13 | 2022-08-02 | 中国医学科学院北京协和医院 | 克罗恩病和肠道溃疡型淋巴瘤的鉴别模型及构建方法 |
| EP3969621A4 (en) | 2019-05-14 | 2023-01-25 | Prometheus Biosciences, Inc. | TL1A PATIENT SELECTION METHODS, SYSTEMS AND DEVICES |
| JP2022541125A (ja) * | 2019-06-27 | 2022-09-22 | サイファー メディシン コーポレーション | 患者を層別化するための分類子の開発 |
| WO2021046412A1 (en) | 2019-09-06 | 2021-03-11 | Cognoa, Inc. | Methods, systems, and devices for the diagnosis of behavioral disorders, developmental delays, and neurologic impairments |
| WO2021097074A1 (en) * | 2019-11-13 | 2021-05-20 | New York University | Intestinal organoid co-culture systems and methods for treating or preventing a disease or disorder associated with immune response-mediated tissue injury |
| WO2022051245A2 (en) * | 2020-09-01 | 2022-03-10 | Scipher Medicine Corporation | Methods and systems for predicting response to anti-tnf therapies |
| US20230352174A1 (en) * | 2020-12-29 | 2023-11-02 | Kpn Innovations, Llc. | Systems and methods for generating a parasitic infection program |
| US20220326255A1 (en) * | 2021-04-01 | 2022-10-13 | Medibeacon Inc. | Methods of monitoring mucosal healing |
| US20240395384A1 (en) * | 2021-09-30 | 2024-11-28 | Prometheus Laboratories Inc. | Patient centric precision model for anti-tnf therapy |
| EP4415607A4 (en) * | 2021-10-15 | 2025-08-27 | Univ Indiana Trustees | Method for the detection of fracture-related infection (FRI) |
| CN114859060B (zh) * | 2022-05-06 | 2025-01-28 | 广州市胸科医院 | 一种细胞因子组及其应用 |
| US20240120050A1 (en) * | 2022-10-07 | 2024-04-11 | Insight Direct Usa, Inc. | Machine learning method for predicting a health outcome of a patient using video and audio analytics |
| US12362058B2 (en) | 2023-01-23 | 2025-07-15 | Kpn Innovations, Llc. | Apparatus and method for using a feedback loop to optimize meals |
| US11887720B1 (en) * | 2023-01-23 | 2024-01-30 | Kpn Innovations, Llc | Apparatus and method for using a feedback loop to optimize meals |
| WO2025250715A1 (en) * | 2024-05-30 | 2025-12-04 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods and related aspects for rapid cytokine detection for inflammatory disease diagnosis |
| US20260188467A1 (en) * | 2024-12-27 | 2026-07-02 | Center for Social Dynamics, LLC | Parallel Processing Systems and Methods For Real-Time Multimodal Behavioral Classification Using Neural Networks With Dynamic Content Adaptation |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1262493A1 (en) | 1992-10-29 | 2002-12-04 | Bayer Corporation | Diagnostic assay for latent matrix metalloproteinase no. 9 |
| US5830675A (en) | 1993-03-10 | 1998-11-03 | Cedars-Sinai Medical Center | Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis, primary sclerosing cholangitis, or type 1 autoimmune hepatitis |
| EP0615129B1 (en) | 1993-03-10 | 2000-05-31 | Cedars-Sinai Medical Center | Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis or primary sclerosing cholangitis |
| US20020025553A1 (en) | 1996-01-04 | 2002-02-28 | Ying-Fei Wei | Transforming growth factor alpha HIII |
| US6074835A (en) | 1996-04-12 | 2000-06-13 | Regents Of The Univ. Of California | Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using histone H1 |
| US6033864A (en) | 1996-04-12 | 2000-03-07 | The Regents Of The University Of California | Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens |
| US6319899B1 (en) | 1997-09-17 | 2001-11-20 | The Nemours Foundation | Method and composition for the treatment of inflammatory bowel disease |
| US6218129B1 (en) | 1998-05-15 | 2001-04-17 | Prometheus Laboratories, Inc. | Inflammatory bowel disease first step assay system |
| RU2141332C1 (ru) | 1998-06-24 | 1999-11-20 | Научно-исследовательский институт фармакологии Томского научного центра РАМН | Противоязвенное средство и способ его получения |
| US6406862B1 (en) | 1998-10-06 | 2002-06-18 | The United States Of America As Represented By The Secretary Of The Army | Dip-stick assay for C-reactive protein |
| US6309643B1 (en) | 1999-04-30 | 2001-10-30 | The Regents Of The University Of California | IBD-associated microbial antigens and methods of using same |
| FR2802536B1 (fr) | 1999-11-23 | 2003-06-13 | Chru Lille | Oligomannosides de synthese, leur preparation et leur utilisation a la detection d'anticorps et a la prevention d'infections |
| FR2806739B1 (fr) | 2000-03-27 | 2005-02-18 | Fond Jean Dausset Ceph | Genes impliques dans les maladies inflammatoires de l'intestin et leur utilisation |
| US6838250B2 (en) | 2000-03-31 | 2005-01-04 | Ortho-Clinical Diagnostics, Inc. | Immunoassay for C-reactive protein |
| US7138237B1 (en) | 2000-05-19 | 2006-11-21 | Cedars-Sinai Medical Center | Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen |
| US7153660B2 (en) | 2000-10-13 | 2006-12-26 | Children's Medical Center Corporation | Non-invasive enzyme screen for tissue remodelling-associated conditions |
| DK1330525T3 (da) | 2000-10-30 | 2013-03-04 | Univ Michigan | NOD2-nukleinsyrer og proteiner |
| CA2427471C (en) | 2000-10-30 | 2010-12-21 | The Regents Of The University Of Michigan | Nod2 nucleic acids and proteins |
| ES2325059T3 (es) | 2000-11-14 | 2009-08-25 | Techlab, Inc. | Metodo para diferenciar el sindrome del intestino irritable de la enfermedad inflamatoria intestinal (ibd) y para seguir personas con ibd usando la lactoferrina endogena total como marcador. |
| CA2458667A1 (en) | 2001-08-30 | 2003-03-13 | The University Of Pittsburgh Of The Commonwealth System Of Higher Educat Ion Of Pennsylvania | Method for predicting the outcome of an infection |
| US20050154536A1 (en) | 2001-08-30 | 2005-07-14 | The University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Two-part drug discovery system |
| EP1581119B1 (en) | 2001-12-17 | 2013-01-30 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of inflammatory bowel disease |
| US20040053263A1 (en) | 2002-08-30 | 2004-03-18 | Abreu Maria T. | Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease |
| DE60321027D1 (de) | 2002-10-25 | 2008-06-26 | Techlab Inc | Diagnostisches panel ibd-first chek fur entzundliche darmerkrankung (ibd) und reizkolon |
| US20040197304A1 (en) | 2003-04-01 | 2004-10-07 | The Procter & Gamble Company And Alimentary Health, Ltd. | Methods of determining efficacy of treatments of inflammatory diseases of the bowel |
| US7662569B2 (en) | 2003-04-11 | 2010-02-16 | Cedars-Sinai Medical Center | Methods of assessing Crohn's disease patient phenotype by I2 serologic response |
| WO2005009339A2 (en) | 2003-05-30 | 2005-02-03 | Pathway Diagnostics Corporation, Inc. (a Delaware Corporation) | Inflammatory bowel diseases |
| KR20060022289A (ko) | 2003-06-23 | 2006-03-09 | 제네틱스 인스티튜트, 엘엘씨 | 인터류킨-22 에 대한 항체 및 그의 용도 |
| CA2549971A1 (en) | 2003-11-03 | 2005-05-12 | Duke University | Methods of identifying individuals at risk of perioperative bleeding, renal dysfunction or stroke |
| DOP2005000002A (es) | 2004-01-09 | 2005-08-15 | Pfizer | "anticuerpos contra madcam" |
| FI119572B (fi) | 2004-03-05 | 2008-12-31 | Biohit Oyj | Menetelmä vatsan limakalvon tilan ennustamiseksi |
| WO2006012472A1 (en) | 2004-07-21 | 2006-02-02 | Qualyst, Inc. | Apparatus, kits and methods for evaluating binding interactions, for detecting and quantifying binding molecules, and for sample preparation |
| US20080086272A1 (en) | 2004-09-09 | 2008-04-10 | Universite De Liege Quai Van Beneden, 25 | Identification and use of biomarkers for the diagnosis and the prognosis of inflammatory diseases |
| AR051444A1 (es) | 2004-09-24 | 2007-01-17 | Centocor Inc | Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos |
| US7462446B2 (en) | 2005-03-18 | 2008-12-09 | University Of Washington | Magnetic nanoparticle compositions and methods |
| CA2963828A1 (en) | 2005-10-26 | 2007-05-03 | Novartis Ag | Novel use of il-1beta compounds |
| CN101472611A (zh) | 2006-06-19 | 2009-07-01 | 惠氏公司 | 调节il-22和il-17的方法 |
| US20080085524A1 (en) * | 2006-08-15 | 2008-04-10 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
| CN104198705B (zh) | 2006-09-21 | 2017-06-09 | 雀巢产品技术援助有限公司 | 检测稀有循环细胞内多种信号转导分子的基于抗体的阵列 |
| WO2008067042A2 (en) | 2006-10-10 | 2008-06-05 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Modeling wound healing |
| WO2008095136A2 (en) | 2007-01-31 | 2008-08-07 | Henkin Robert I | Methods for detection of biological substances |
| GB2447865A (en) | 2007-03-30 | 2008-10-01 | Ethicon Inc | Diagnostic markers of wound infection |
| US20100255513A1 (en) | 2007-03-30 | 2010-10-07 | Denson Lee A | Serological markers of inflammatory bowel disease phenotype and disease progression |
| WO2008147869A2 (en) * | 2007-05-22 | 2008-12-04 | Centocor, Inc. | Markers and methods for assessing and treating crohn's disease and related disorders |
| NZ582618A (en) | 2007-07-13 | 2012-07-27 | Prometheus Lab Inc | Drug selection for lung cancer therapy using antibody-based arrays |
| ES2553390T3 (es) | 2008-02-25 | 2015-12-09 | Nestec S.A. | Método para la detección de receptores truncados intracelulares |
| SG177937A1 (en) | 2008-03-26 | 2012-02-28 | Theranos Inc | Methods and systems for assessing clinical outcomes |
| WO2009117791A2 (en) * | 2008-03-28 | 2009-10-01 | Katholieke Universiteit Leuven | Mucosal gene signatures |
| JP2012500993A (ja) * | 2008-08-25 | 2012-01-12 | ヤンセン バイオテツク，インコーポレーテツド | 潰瘍性大腸炎及び関連した疾患における抗ｔｎｆ処置のためのバイオマーカー |
| AU2009285644B2 (en) * | 2008-08-29 | 2015-08-20 | Janssen Biotech, Inc. | Markers and methods for assessing and treating ulcerative colitis and related disorders using a 20 gene panel |
| NZ619527A (en) | 2009-04-14 | 2015-06-26 | Nestec Sa | Inflammatory bowel disease prognostics |
| WO2010127057A2 (en) | 2009-05-01 | 2010-11-04 | Meso Scale Technologies, Llc. | Biomarkers of therapeutic responsiveness |
| NZ596468A (en) | 2009-05-14 | 2013-11-29 | Nestec Sa | Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy |
| ES2509616T3 (es) | 2009-06-25 | 2014-10-17 | Nestec S.A. | Procedimientos de diagnóstico del síndrome del intestino irritable |
| JP5795311B2 (ja) | 2009-07-15 | 2015-10-14 | ネステク ソシエテ アノニム | 抗体ベースのアレイを使用する胃癌療法のための薬物選択 |
| US9950062B2 (en) | 2009-09-02 | 2018-04-24 | Glaxosmithkline Biologicals Sa | Compounds and compositions as TLR activity modulators |
| CA2777800C (en) * | 2009-10-15 | 2019-11-12 | Crescendo Bioscience | Biomarkers and methods for measuring and monitoring inflammatory disease activity |
| DK2491385T3 (en) | 2009-10-20 | 2017-08-28 | Diatech Holdings Inc | PROXIMITY-MEDIED ASSAYS FOR DETECTING ONCOGEN FUSION PROTEINS |
| CN104634955B (zh) | 2009-10-26 | 2016-09-14 | 雀巢产品技术援助有限公司 | 检测抗-tnf药物和自身抗体的试验 |
| CA2781654A1 (en) | 2009-11-25 | 2011-06-03 | Hua Gong | Novel genomic biomarkers for irritable bowel syndrome diagnosis |
| US20130071860A1 (en) | 2010-02-24 | 2013-03-21 | Matthew B. Hale | Methods for autoimmune disease diagnosis, prognosis, and treatment` |
| EP2576838A4 (en) | 2010-06-04 | 2019-05-15 | Nestec S.A. | METHOD FOR IMPROVING DIAGNOSIS OF INFLAMMATORY ENDURANCE |
| WO2012024543A1 (en) | 2010-08-18 | 2012-02-23 | Caris Life Sciences Luxembourg Holdings | Circulating biomarkers for disease |
| SG191230A1 (en) | 2010-12-23 | 2013-07-31 | Nestec Sa | Drug selection for malignant cancer therapy using antibody-based arrays |
| EP2681552A2 (en) | 2011-03-02 | 2014-01-08 | Nestec S.A. | Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures |
| CA3295783A1 (en) | 2011-05-10 | 2026-03-02 | Prometheus Laboratories, Inc. | Methods of disease activity profiling for personalized therapy management |
| KR101851425B1 (ko) | 2011-09-02 | 2018-04-23 | 네스텍 소시에테아노님 | 치료 효능 결정을 위한 신호 경로 단백질의 프로파일링 |
| WO2013059732A1 (en) | 2011-10-21 | 2013-04-25 | Nestec S.A. | Methods for improving inflammatory bowel disease diagnosis |
| MD20140108A2 (ro) | 2012-02-29 | 2015-03-31 | Gilead Biologics, Inc. | Anticorpi împotriva metaloproteinazei 9 matriciale |
| ES2638971T3 (es) | 2012-10-05 | 2017-10-24 | Nestec S.A. | Métodos para predecir y monitorizar la cicatrización de la mucosa |
| US20140113306A1 (en) | 2012-10-17 | 2014-04-24 | Rutgers, The State University Of New Jersey | Diagnostic and screening methods for inflammation |
| CA3215087A1 (en) | 2013-01-03 | 2014-07-10 | Meso Scale Technologies, Llc | Assay panels |
| US20140236166A1 (en) | 2013-02-15 | 2014-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Biomarkers for distinguishing benign, pre-malignant, and malignant pancreatic cysts |
| WO2015110989A1 (en) | 2014-01-23 | 2015-07-30 | Nestec S.A. | Biomarker panel for assessment of mucosal healing |
| JP6904905B2 (ja) | 2014-12-24 | 2021-07-21 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 抗α４β７インテグリン抗体による治療の結果の予測 |
| EP3247343A1 (en) | 2015-01-23 | 2017-11-29 | Nestec S.A. | Nutritional composition useful in the treatment of ibd patients |
| EP3978530A1 (en) | 2015-02-26 | 2022-04-06 | F. Hoffmann-La Roche AG | Integrin beta7 antagonists and methods of treating crohn's disease |
| KR20200009095A (ko) | 2017-05-31 | 2020-01-29 | 프로메테우스 바이오사이언시즈, 인크. | 크론병 환자에서 점막 치유를 평가하는 방법 |
| WO2020117795A1 (en) | 2018-12-04 | 2020-06-11 | Prometheus Biosciences, Inc. | Assessment and monitoring of mucosal healing in children and adults with crohn's disease |
-
2012
- 2012-05-10 CA CA3295783A patent/CA3295783A1/en active Pending
- 2012-05-10 SG SG2013080585A patent/SG194710A1/en unknown
- 2012-05-10 WO PCT/US2012/037375 patent/WO2012154987A1/en not_active Ceased
- 2012-05-10 MX MX2013013096A patent/MX362132B/es active IP Right Grant
- 2012-05-10 EP EP12722621.5A patent/EP2707504A1/en not_active Ceased
- 2012-05-10 JP JP2014510475A patent/JP2014517279A/ja active Pending
- 2012-05-10 CN CN201280034138.2A patent/CN103649336A/zh active Pending
- 2012-05-10 AU AU2012253422A patent/AU2012253422B2/en not_active Ceased
- 2012-05-10 RU RU2013154566/15A patent/RU2013154566A/ru unknown
- 2012-05-10 CN CN201910821596.4A patent/CN110544517A/zh active Pending
- 2012-05-10 BR BR112013028808A patent/BR112013028808A2/pt not_active Application Discontinuation
- 2012-05-10 KR KR1020137032638A patent/KR20140032424A/ko not_active Ceased
-
2013
- 2013-10-28 IL IL229120A patent/IL229120B/en active IP Right Grant
- 2013-11-05 US US14/072,746 patent/US10086072B2/en active Active
- 2013-11-08 MX MX2018008324A patent/MX2018008324A/es unknown
- 2013-12-09 ZA ZA2013/09258A patent/ZA201309258B/en unknown
-
2017
- 2017-11-22 JP JP2017225123A patent/JP2018072349A/ja not_active Ceased
-
2018
- 2018-08-24 US US16/112,242 patent/US11160863B2/en active Active
-
2020
- 2020-01-17 JP JP2020006298A patent/JP2020098213A/ja active Pending
-
2021
- 2021-09-24 US US17/484,786 patent/US12485171B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013154566A (ru) | Способы анализа профиля активности болезни с целью проведения индивидуального лечения | |
| Agache et al. | Advances and highlights in asthma in 2021 | |
| Moschen et al. | IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting | |
| Smolen et al. | Patients with rheumatoid arthritis in clinical care | |
| Saleem et al. | Does the use of tumour necrosis factor antagonist therapy in poor prognosis, undifferentiated arthritis prevent progression to rheumatoid arthritis? | |
| RU2016147569A (ru) | Способы лечения воспалительного заболевания кишечника | |
| Dunne et al. | Effect of post-exercise hydrotherapy water temperature on subsequent exhaustive running performance in normothermic conditions | |
| JP2015532425A5 (cg-RX-API-DMAC10.html) | ||
| Caruso et al. | Biologic agents for severe asthma patients: clinical perspectives and implications | |
| Felipez et al. | North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition position paper on the therapeutic drug monitoring in pediatric inflammatory bowel disease | |
| Linares et al. | Transcriptional regulation of chemokine network by biologic monotherapy in ileum of patients with Crohn’s disease | |
| Diver et al. | Beyond T2-inflammation: What Does the Future Hold for Severe Asthma? | |
| Brightling et al. | Beyond T2-inflammation: What Does the Future Hold for Severe Asthma? | |
| Graham et al. | Cost-effectiveness in the second-line treatment of non-small cell lung cancer (NSCLC) in the US | |
| van de Putte | ARD launches an advanced online publication programme | |
| Lee et al. | Changes in Gene Expression in Fatty Acid Metabolism and De Novo Lipogenesis Are Conserved in Human CKD and Animal Models: SA-OR96 | |
| Gote-Schniering et al. | AB1145 DECIPHERING THE SPATIAL HETEROGENEITY OF SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE BY INTEGRATIVE RADIOMICS AND SINGLE-NUCLEUS TRANSCRIPTOMIC PROFILING | |
| Onishi et al. | Bub1 Is a Potential Mediator of TGFβ-Induced Renal Fibrosis: SA-OR94 | |
| Sharma et al. | Protective Role of RBPjk in HIV-Related CKD: SA-OR95 | |
| Blaker et al. | 567 Optimizing the Response to Thiopurine Therapy: A Search for Novel Explanations for Thiopurine Hypermethylation | |
| Van den Bemt | Optimizing Pharmacotherapy in Patients with Rheumatoid Arthritis. An Individualized Approach. | |
| Miyagawa et al. | OP0321 Precision medicine using different biological dmards based on characteristic phenotypes of peripheral t helper cells in psoriatic arthritis | |
| Rinaldi et al. | P6341 Haemodynamic and exercise effects of different types of initial oral combination therapy in pulmonary arterial hypertension | |
| Nair | Decision making in rheumatoid arthritis treatment: from population to patients | |
| FREEMAN | Elderly Receive Suboptimal RA Treatment |